Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.

Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, Mayes MD, Nash RA, Crofford LJ, Eggleston B, Castina S, Griffith LM, Goldstein JS, Wallace D, Craciunescu O, Khanna D, Folz RJ, Goldin J, St Clair EW, Seibold JR, Phillips K, Mineishi S, Simms RW, Ballen K, Wener MH, Georges GE, Heimfeld S, Hosing C, Forman S, Kafaja S, Silver RM, Griffing L, Storek J, LeClercq S, Brasington R, Csuka ME, Bredeson C, Keever-Taylor C, Domsic RT, Kahaleh MB, Medsger T, Furst DE, SCOT Study Investigators
N Engl J Med. 2018 378 (1): 35-47

PMID: 29298160 · PMCID: PMC5846574 · DOI:10.1056/nejmoa1703327

MeSH Terms (19)

Adolescent Adult Aged Cyclophosphamide Disease-Free Survival Female Follow-Up Studies Hematopoietic Stem Cell Transplantation Humans Immunosuppressive Agents Infections Intention to Treat Analysis Kaplan-Meier Estimate Male Middle Aged Scleroderma, Systemic Transplantation, Autologous Transplantation Conditioning Young Adult

Connections (1)

This publication is referenced by other Labnodes entities:

Links